Table 1.
The clinical characteristics of patients with non-HT and HT in the training, validation, and prospective test cohorts
| Training cohort |
Validation cohort |
Prospective test cohort |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Non-HT |
HT |
p | Non-HT |
HT |
p | Non-HT |
HT |
p | |
| N = 348 | N = 375 | N = 32 | N = 48 | N = 229 | N = 191 | ||||
| Sex | 0.067 | 1 | 0.003 | ||||||
| Female | 95 (27.3) | 127 (33.9) | 11 (34.4) | 16 (33.3) | 56 (24.5) | 73 (38.2) | |||
| Male | 253 (72.7) | 248 (66.1) | 21 (65.6) | 32 (66.7) | 173 (75.5) | 118 (61.8) | |||
| Age | <0.001 | 0.819 | 0.001 | ||||||
| <45 | 155 (44.5) | 236 (62.9) | 15 (46.9) | 25 (52.1) | 94 (41.0) | 110 (57.6) | |||
| ≥45 | 193 (55.5) | 139 (37.1) | 17 (53.1) | 23 (47.9) | 135 (59.0) | 81 (42.4) | |||
| T stage | 0.782 | 0.930 | 0.748 | ||||||
| T1 | 30 (8.6) | 32 (8.5) | 4 (12.5) | 5 (10.4) | 13 (5.7) | 12 (6.3) | |||
| T2 | 53 (15.2) | 65 (17.3) | 4 (12.5) | 7 (14.6) | 23 (10.0) | 19 (9.9) | |||
| T3 | 181 (52.0) | 182 (48.5) | 17 (53.1) | 23 (47.9) | 131 (57.2) | 117 (61.3) | |||
| T4 | 84 (24.1) | 96 (25.6) | 7 (21.9) | 13 (27.1) | 62 (27.1) | 43 (22.5) | |||
| N stage | 0.064 | 0.016 | 0.108 | ||||||
| N0 | 55 (15.8) | 37 (9.9) | 6 (18.8) | 4 (8.3) | 28 (12.2) | 11 (5.8) | |||
| N1 | 127 (36.5) | 142 (37.9) | 19 (59.4) | 17 (35.4) | 89 (38.9) | 80 (41.9) | |||
| N2 | 123 (35.3) | 134 (35.7) | 3 (9.4) | 18 (37.5) | 68 (29.7) | 67 (35.1) | |||
| N3 | 43 (12.4) | 62 (16.5) | 4 (12.5) | 9 (18.8) | 44 (19.2) | 33 (17.3) | |||
| Overall stage | 0.635 | 0.112 | 0.611 | ||||||
| Ⅰ | 13 (3.7) | 15 (4.0) | 3 (9.4) | 0 (0.0) | 4 (1.7) | 4 (2.1) | |||
| Ⅱ | 38 (10.9) | 41 (10.9) | 3 (9.4) | 2 (4.2) | 19 (8.3) | 14 (7.3) | |||
| Ⅲ | 181 (52.0) | 178 (47.5) | 15 (46.9) | 24 (50.0) | 108 (47.2) | 102 (53.4) | |||
| Ⅳ | 116 (33.3) | 141 (37.6) | 11 (34.4) | 22 (45.8) | 98 (42.8) | 71 (37.2) | |||
| Treatment | 0.026 | 0.476 | 0.301 | ||||||
| RT alone | 38 (10.9) | 27 (7.2) | 3 (9.4) | 1 (2.1) | 20 (8.7) | 9 (4.7) | |||
| CCRT | 163 (46.8) | 151 (40.3) | 13 (40.6) | 24 (50.0) | 107 (46.7) | 87 (45.5) | |||
| IC + CCRT | 139 (39.9) | 190 (50.7) | 15 (46.9) | 22 (45.8) | 98 (42.8) | 89 (46.6) | |||
| IC + RT | 8 (2.3) | 7 (1.9) | 1 (3.1) | 1 (2.1) | 4 (1.7) | 6 (3.1) | |||
Abbreviation: CCRT, concurrent chemoradiotherapy; HT, hypothyroidism; IC, induction chemotherapy; RT, radiotherapy.